ImmuLogic cocaine vaccine therapy R&D to be funded by NIDA grant; clinicals forecast for early to mid-1997.
IMMULOGIC COCAINE VACCINE R&D WILL BE SUPPORTED BY NIDA through a Small Business Innovation Research grant, Waltham, Mass.-based ImmuLogic announced Aug. 2. The $700,000 SBIR grant "will make it possible to expeditiously optimize the design of the cocaine vaccine and its administration to humans while assessing the vaccine's efficacy in further animal models." ImmuLogic also may employ the same technology to treat nicotine addiction, the firm said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth